Cefdinir: Nursing Drug Guide, C. diff Risk & Hold Rules
Oral third-generation cephalosporin guide for nurses: screen penicillin and cephalosporin allergy history, watch for watery or bloody diarrhea suggesting C. difficile, separate iron and antacids by 2 hours, and adjust doses when creatinine clearance is below 30 mL/min.
Clostridioides difficile-associated diarrhea (CDAD) has been reported with cefdinir and may range from mild diarrhea to fatal colitis—including symptoms that begin during therapy or more than two months after the last dose. If CDAD is suspected, ongoing antibacterial therapy not directed against C. difficile may need to be discontinued per prescriber guidance. Before the first dose, obtain allergy history for cephalosporins, penicillins, and other beta-lactams; cross-hypersensitivity may occur in up to 10% of penicillin-allergic patients. Serious reactions require stopping the drug and emergency treatment (epinephrine, airway support, IV fluids, antihistamines, corticosteroids) as clinically indicated per labeling.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, confirm allergy history (cephalosporin, penicillin, other beta-lactams), teach patients that new watery or bloody diarrhea can signal C. difficile even weeks after therapy ends, and separate iron or aluminum/magnesium antacids from cefdinir by at least 2 hours. Reduce the dose when creatinine clearance is below 30 mL/min—high drug levels and seizures have been reported with cephalosporins when renal dosing is missed.
Most common brand names
Cefdinir is a prescription oral cephalosporin. The most recognized U.S. brand is Omnicef (capsules and powder for oral suspension). Generic cefdinir is widely available—always match the ordered formulation (capsule vs suspension) and strength on the MAR.
Do not confuse cefdinir with other cephalosporins such as cephalexin (first generation) or amoxicillin (penicillin class) when verifying allergies and duplicate antibiotic therapy.
Why we give it — Indications
Cefdinir treats mild to moderate infections caused by susceptible organisms when culture, susceptibility, or local epidemiology supports its use. Labeling stresses using cefdinir only for proven or strongly suspected bacterial infections to limit resistance.
| Use (labeled) | Detail |
|---|---|
| Community-acquired pneumonia | Adults/adolescents ≥13 years: 300 mg q12h for 10 days (BID required—once-daily dosing not studied for pneumonia per labeling) |
| Acute exacerbations of chronic bronchitis | 300 mg q12h for 5–10 days or 600 mg q24h for 10 days |
| Acute maxillary sinusitis | 300 mg q12h or 600 mg q24h for 10 days; pediatric use supported age 6 months through 12 years |
| Pharyngitis / tonsillitis | 300 mg q12h or 600 mg q24h for 5–10 days; effective for eradicating Streptococcus pyogenes from the oropharynx but not studied for rheumatic-fever prevention (only IM penicillin has that evidence per labeling) |
| Uncomplicated skin and skin structure infections | Adults: 300 mg q12h for 10 days; pediatrics: 7 mg/kg q12h for 10 days (BID required for skin infections) |
| Pediatric otitis media | Age 6 months–12 years: 7 mg/kg q12h for 5–10 days or 14 mg/kg q24h for 10 days (total daily dose 14 mg/kg, max 600 mg/day) |
On a small screen, swipe or scroll sideways to see the full table.
Nurses often see cefdinir for ear pain, sore throat, sinusitis, bronchitis, pneumonia, or cellulitis when the prescriber selects an oral cephalosporin—confirm the indication matches the order and culture plan.
How it works
Cefdinir is a third-generation cephalosporin. Bactericidal activity results from inhibition of bacterial cell-wall synthesis. It is stable against some beta-lactamases. Renal excretion is the predominant elimination pathway (mean plasma half-life approximately 1.7 hours in adults with normal renal function). Activity is primarily due to parent drug; cefdinir is not appreciably metabolized per prescribing information.
Dosing overview
Total daily dose is 600 mg for adults/adolescents (≥13 years) and 14 mg/kg/day (maximum 600 mg/day) for pediatric patients age 6 months through 12 years. Verify weight, renal function, infection type, and whether once-daily dosing is appropriate—once-daily regimens are not studied for pneumonia or skin infections (use BID).
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy or prescriber for guidance if a dose is missed, especially near the end of a fixed-duration course.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Peak (oral) | 2–4 hours postdose (capsule or suspension) | Symptom improvement may lag behind peak levels; reassess clinical response over 48–72 hours |
| Half-life | Mean ~1.7 (±0.6) hours in adults with normal renal function | Prolonged in renal impairment—dose reduction required when CrCl <30 mL/min |
| Elimination | Principally renal; ~18% of 300 mg dose recovered unchanged in urine (adults) | Trend creatinine and fluid status; hemodialysis removes drug |
| Duration of therapy | 5–10 days depending on infection (see dosing table) | Document completion of full course unless prescriber discontinues early for toxicity or culture data |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Allergy history: cephalosporins, penicillins, carbapenems, and prior beta-lactam reactions; note that cross-hypersensitivity among beta-lactams may occur in up to 10% of penicillin-allergic patients per labeling
- Current and recent antibiotics—duplicate beta-lactam therapy increases resistance and CDAD risk; perform medication reconciliation
- Renal function (serum creatinine, estimated CrCl or eGFR)—adjust dose when CrCl <30 mL/min
- Scheduled iron, multivitamins with iron, or aluminum/magnesium antacids—plan separation by at least 2 hours
- Baseline symptoms: fever, localized infection signs, and whether diarrhea is already present before starting therapy
Contraindications
- Known allergy to the cephalosporin class of antibiotics
Important interactions
| Drug / substance | Effect | Nursing action |
|---|---|---|
| Iron supplements / iron-fortified foods | 60 mg elemental iron reduced absorption extent by 80%; reddish stools possible with iron co-administration | Give cefdinir at least 2 hours before or after iron; teach that red stool may be benign discoloration, not always GI bleeding |
| Aluminum- or magnesium-containing antacids | Concurrent antacid reduces rate and extent of absorption (~40%); no significant effect if antacid is 2 hours before or after | Separate antacid and cefdinir by at least 2 hours |
| Probenecid | Inhibits renal excretion—approximately doubles AUC and prolongs half-life | Notify pharmacist if probenecid is ordered; monitor for toxicity if combination is required |
| Urinalysis interference | False-positive glucose (Clinitest, Benedict, Fehling) and false-positive ketones (nitroprusside); direct Coombs test may be positive | Use enzyme-based glucose strips (e.g., Clinistix) per labeling; document antibiotic on lab requisition |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral capsule (commonly 300 mg) or oral suspension (reconstituted 125 mg/5 mL or 250 mg/5 mL). May be administered without regard to meals per labeling.
- Shake suspension well before each dose; use an oral syringe or calibrated device—not household spoons
- Complete the full prescribed course unless toxicity or prescriber discontinuation; stopping early promotes resistance
- Separate iron supplements and aluminum/magnesium antacids by at least 2 hours before or after the dose
- Follow medication administration rights; document dose, time, route, and patient tolerance
Institutional protocols and product formulations may vary for reconstitution volume, storage after mixing, and beyond-use dating. Verify pharmacy label directions before first dose.
Expected therapeutic response
- Decreasing fever and improving infection-related symptoms over 48–72 hours when the organism is susceptible
- Stable or improving vital signs without new hypotension, tachycardia, or respiratory deterioration
- Absence of new watery or bloody diarrhea, abdominal distention, or toxicity signs suggesting CDAD
- Culture or clinical follow-up per prescriber when symptoms do not improve within expected timeframe
Red flags — Stop and act
Stop the dose, notify the prescriber, and escalate urgently when any of the following occur:
- Watery or bloody stools, abdominal cramping, or diarrhea with fever during or after therapy (consider CDAD—even months later)
- Blood in stool, melena, or severe abdominal pain
- Rash, hives, facial or laryngeal swelling, wheezing, or signs of anaphylaxis
- Seizure activity—cephalosporins have triggered seizures, especially when dosage was not reduced in renal impairment per labeling
- New jaundice, dark urine, or severe GI bleeding (postmarketing reports include hepatic failure and hemorrhagic colitis)
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Diarrhea | 15% in U.S. adult/adolescent capsule trials; common reason for discontinuation | Differentiate benign antibiotic-associated loose stools from CDAD; obtain stool studies and contact prescriber if watery/bloody |
| Nausea, abdominal pain, dyspepsia | 3%, 1%, <1% respectively in U.S. adult trials | Supportive care; hold and notify if persistent vomiting or signs of colitis |
| Headache | 2% in U.S. adult trials | Monitor trend; investigate if accompanied by fever, stiff neck, or altered mental status |
| Rash | 0.9% in U.S. adult trials; serious skin reactions reported postmarketing (SJS, TEN) | Stop cefdinir at first rash; escalate for mucosal involvement or systemic symptoms |
| Vaginal moniliasis / vaginitis | 4% and 1% of women in U.S. adult trials | Teach patients to report vaginal itching or discharge; treat per prescriber |
| CDAD / pseudomembranous colitis | Serious; may be fatal | Hold antibiotic, isolation precautions per facility, notify prescriber and infection prevention |
| Anaphylaxis, serum sickness-like reactions | Rare postmarketing; fatalities reported | Stop drug permanently; emergency response per protocol |
On a small screen, swipe or scroll sideways to see the full table.
Pediatric suspension trial frequencies differ slightly; diarrhea remained the leading cause of discontinuation (2% of pediatric patients).
Overdose, toxicity, and antidote
Information on cefdinir overdosage in humans is not available in the reviewed prescribing information.
Expected signs (other beta-lactams)
Antidote / removal
No specific antidote is listed. Hemodialysis removes cefdinir from the body and may be useful after serious toxic reactions, particularly when renal function is compromised. Contact local poison control or medical toxicology services per facility protocol and local emergency guidance.
Several cephalosporins have triggered seizures when dosage was not reduced in renal impairment. If seizures occur during therapy, discontinue the drug and treat per seizure protocol.
Look-alike / sound-alike and error prevention
- Cefdinir vs cephalexin vs cefuroxime—verify generic name on MAR; all are cephalosporins but differ in generation, spectrum, and dosing
- Cefdinir vs amoxicillin—sound-alike risk in verbal orders; confirm allergy class and ordered drug
- Capsule vs suspension—pediatric weight-based mL volumes differ by concentration (125 vs 250 mg/5 mL)
- Once-daily vs BID—once-daily dosing is not studied for pneumonia or skin infections; do not consolidate BID orders without prescriber approval
- Reddish stool—may be harmless cefdinir–iron complex; still investigate true GI bleeding or CDAD when clinically indicated
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food timing | May take without regard to meals; still separate iron and antacids by 2 hours |
| Suspension technique | Shake well; measure with oral syringe; refrigerate per pharmacy label after reconstitution |
| Enteral tube | Institutional protocols and product formulations may vary; consult pharmacy for tube administration and flush volumes |
| Lab interference | False-positive urine glucose and ketones; use enzyme-based glucose monitoring per labeling |
| Commonly missed | Home iron vitamins taken with antibiotic; duplicate oral cephalosporin from recent clinic visit |
| Ask pharmacy when | CrCl <30, hemodialysis schedule, probenecid co-therapy, or suspension volume for weight |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Penicillin allergy / prior beta-lactam reaction | Use caution in penicillin-sensitive patients; cross-reactivity may occur in up to 10% per labeling. Stop immediately for anaphylaxis or serious hypersensitivity. |
| Renal impairment / hemodialysis | Reduce dose when CrCl <30 mL/min; hemodialysis patients need supplemental post-dialysis doses per labeling. Monitor for seizures if doses are not adjusted. |
| Older adults | No routine dose adjustment unless renal function is markedly compromised; geriatric trials reported lower diarrhea rates than younger adults |
| Pediatrics <6 months | Safety and efficacy not established in neonates and infants <6 months |
| Pregnancy | Pregnancy Category B; no adequate human studies—use only if clearly needed |
| Lactation | After single 600 mg dose, cefdinir was not detected in human breast milk per labeling. Weigh infant risk and clinical need with prescriber. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Stool frequency and character—especially watery, bloody, or foul-smelling diarrhea; obtain stool culture or C. diff testing per protocol when CDAD is suspected
- Allergic symptoms: rash, pruritus, urticaria, respiratory distress, angioedema
- Infection response: temperature trend, localized signs (throat, ear, skin, or urinary symptoms per indication), WBC if ordered
- Renal function and hydration when CrCl is reduced—review basic metabolic panel trends per prescriber
Document
- Allergy verification, dose (mg and mL for suspension), route, time, and patient education on diarrhea and iron separation
- Stool character changes, isolation precautions initiated, and prescriber/pharmacy notifications
- Completion of antibiotic course or early discontinuation reason (toxicity, culture-directed change)
Patient teaching
- Take the full course even if you feel better—stopping early can cause resistant bacteria
- Report watery or bloody diarrhea, severe stomach pain, or fever right away—these can occur during treatment or weeks afterward
- Take iron vitamins or antacids at least 2 hours before or after cefdinir; red-colored stool may occur with iron and is not always blood
- Report rash, itching, swelling of the face or throat, or trouble breathing immediately
- Shake liquid medicine well and use only the measuring device provided; do not share antibiotics with others
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known cephalosporin allergy or active serious hypersensitivity (urticaria with systemic symptoms, angioedema, anaphylaxis)
- New watery or bloody diarrhea, abdominal distention, or clinical suspicion of C. difficile—hold and notify before additional doses
- Order does not reflect renal dose reduction when creatinine clearance is <30 mL/min (adults) or <30 mL/min/1.73 m² (pediatrics)
- Iron supplement or aluminum/magnesium antacid scheduled at the same time and cannot be rescheduled ±2 hours
- Duplicate beta-lactam antibiotic on MAR or home med list without prescriber intent
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Oral cefdinir is convenient for outpatient-style regimens, but nurses remain the safety gate for allergy cross-reactivity, CDAD surveillance, renal dosing, and absorption interactions. Treat every antibiotic course as a stewardship and toxin-monitoring episode—not only an infection-treatment task.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right renal-adjusted dose for CrCl <30
- Verify allergy band matches charted beta-lactam history; escalate ambiguous penicillin allergy entries
- Confirm iron and antacid timing on the MAR; reschedule MAR entries if needed before administration
- Ask about current diarrhea baseline so new symptoms are recognized early
2. High-alert and safety badge
Not a universal high-alert medication, but CDAD and anaphylaxis carry high patient harmApply the same documentation rigor as for high-risk anti-infectives: stool surveillance, allergy escalation, and immediate hold for bloody diarrhea or angioedema.
3. Clinical workflow: hold and question rules
- If diarrhea worsens while on cefdinir, hold the next dose and notify prescriber—do not assume it is a benign side effect until CDAD is ruled out
- If a penicillin-allergic patient develops rash after dose one, stop and clarify whether cephalosporin rechallenge is appropriate
- Contact pharmacy when probenecid, hemodialysis timing, or suspension concentration changes the effective dose
4. Critical teach-back questions
- “What diarrhea symptoms should make you call us immediately?” (Patient should name watery or bloody stools, severe cramps, fever—possible C. difficile.)
- “When should you take your iron vitamin relative to this antibiotic?” (Patient should state at least 2 hours apart before or after cefdinir.)
5. Care coordination
Pharmacist: Renal dose verification, iron/antacid scheduling, probenecid interaction review, and suspension volume checks for pediatric weights
Prescriber / infectious diseases: Notify for suspected CDAD, culture-directed therapy changes, persistent fever, or serious hypersensitivity requiring alternative agents
🧠 Quick mental checklist
- Does this patient have cephalosporin, penicillin, or other beta-lactam allergy documented?
- Is creatinine clearance below 30 mL/min and does the order reflect once-daily 300 mg (adult) or 7 mg/kg (pediatric)?
- Are iron or magnesium/aluminum antacids separated by at least 2 hours?
- Any new watery or bloody diarrhea—could this be C. difficile even after therapy ends?
- Is this the right oral cephalosporin on the MAR (not cephalexin or amoxicillin)?
Cefdinir NCLEX practice questions
Practice NCLEX-style clinical judgment practice for cefdinir using a tabbed outpatient case (MAR, labs, I&O, nursing notes), then priority action, cue recognition (SATA), stool-trend interpretation, matrix urgency for CDAD and allergy findings, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Cefdinir suspension 7 mg/kg PO q12h (250 mg/5 mL) — 0900 given; 2100 due
- Acetaminophen 160 mg PO q6h PRN fever — 1 dose at 1400
- Ferrous sulfate 325 mg PO daily — scheduled 0800 (given before cefdinir)
- 0900 dose given 15 minutes after iron dose (documented as medication error)
- Admission: WBC 14.2 ×10⁹/L; creatinine 0.9 mg/dL; estimated CrCl 88 mL/min
- Day 3: WBC 9.8 ×10⁹/L; temp culture pending
- Stool C. difficile PCR: not yet collected
- Stools day 1–2: formed, 1 per day
- Today (day 3): 4 liquid stools; last stool described as watery with mucus
- Vitals 1600: T 38.1 °C, HR 108, BP 102/64, RR 18, SpO₂ 97% on room air
- Allergies: penicillin — rash as child (documented)
- Parent reports red-colored stool after morning iron; no abdominal pain until this afternoon
- 1600: Child tired, capillary refill 2 s; tolerating sips of water
Answer key & rationale
Frequently asked questions
When should a nurse hold cefdinir and contact the prescriber or pharmacist?
Hold for known allergy to cephalosporins (contraindicated), suspected serious hypersensitivity (rash with systemic symptoms, angioedema, anaphylaxis), watery or bloody diarrhea suggesting Clostridioides difficile-associated diarrhea, or renal impairment requiring dose adjustment that is not reflected in the order (creatinine clearance less than 30 mL/min in adults). Also hold if iron supplements or aluminum/magnesium antacids cannot be separated by at least 2 hours unless pharmacy clarifies timing.
Why must nurses separate cefdinir from iron supplements?
Cefdinir prescribing information states that iron supplements, including multivitamins with iron, interfere with absorption. Concomitant administration of a therapeutic iron supplement containing 60 mg elemental iron reduced extent of absorption by 80%. If iron is required during therapy, cefdinir should be taken at least 2 hours before or after the supplement. Reddish stools may occur when cefdinir is given with iron-containing products due to a nonabsorbable complex in the gastrointestinal tract.
What diarrhea findings suggest C. difficile during cefdinir therapy?
Labeling warns that Clostridioides difficile-associated diarrhea has been reported with cefdinir and may range from mild diarrhea to fatal colitis. CDAD must be considered in any patient who develops diarrhea during or after antibacterial use, including more than two months after the last dose. Watery or bloody stools with or without abdominal cramps and fever warrant urgent evaluation; ongoing antibacterial therapy not directed against C. difficile may need to be discontinued per prescriber and infectious-disease guidance.
How is cefdinir dosed in renal impairment?
For adult patients with creatinine clearance less than 30 mL/min, the dose of cefdinir should be 300 mg once daily. For pediatric patients with creatinine clearance less than 30 mL/min/1.73 m2, the dose should be 7 mg/kg (up to 300 mg) once daily. Patients on chronic hemodialysis require alternate-day dosing with supplemental doses after each dialysis session per prescribing information.
Is cefdinir safe in pregnancy and breastfeeding?
Animal reproduction studies did not show teratogenicity at tested doses, but there are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed per labeling (Pregnancy Category B). Following a single 600 mg dose, cefdinir was not detected in human breast milk. Safety in neonates and infants less than 6 months has not been established.
What is the antidote for cefdinir overdose?
Information on cefdinir overdosage in humans is not available in prescribing information. Overdose with other beta-lactam antibiotics has caused nausea, vomiting, diarrhea, and convulsions. Hemodialysis removes cefdinir and may be useful after serious toxic reactions, particularly if renal function is compromised. Contact local poison control or medical toxicology services per facility protocol; there is no specific reversal agent listed.
References
-
U.S. National Library of Medicine. CEFDINIR capsule — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ba5cb2d-6272-27de-e053-2995a90a58c8
-
U.S. National Library of Medicine. CEFDINIR for oral suspension — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7490df67-56c0-4a1c-8533-2107f3e8aea5
-
Centers for Disease Control and Prevention. Clostridioides difficile infection: information for clinicians.https://www.cdc.gov/cdiff/clinicians/diagnosis.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.